Journal article
Two dicarbonyl compounds, 3-deoxyglucosone and methylglyoxal, differentially modulate dermal fibroblasts
Matrix biology, v 29(2)
2010
PMID: 19800404
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Advanced glycation endproducts accumulate on long-lived proteins such as collagens as a function of diet and age and mediate the cross-linking of those proteins causing changes in collagen pathophysiology resulting in the disruption of normal collagen matrix remodeling. Two commonly studied advanced glycation endproduct precursors 3-deoxyglucosone and methylglyoxal were investigated for their role in the modification of collagen and on extracellular matrix expression. Fibroblasts cultured on methylglyoxal cross-linked matrices increased the expression of collagen, active TGF-beta1, beta1-integrin, and decreased Smad7; whereas 3-deoxyglucosone decreased collagen, active TGF-beta1, beta1-integrin but increased Smad7. Purified collagen modified by 3-deoxyglucosone or methylglyoxal had different molecular weights; methylglyoxal increased the apparent molecular weight by approximately 20
kDa, whereas 3-deoxyglucosone did not. The differences in collagen expression by 3-deoxyglucosone and methylglyoxal raise the provocative idea that a genetic or environmental background leading to the predominance of one of these advanced glycation endproduct precursors may precipitate a fibrotic or chronic wound in susceptible individuals, particularly in the diabetic.
Metrics
Details
- Title
- Two dicarbonyl compounds, 3-deoxyglucosone and methylglyoxal, differentially modulate dermal fibroblasts
- Creators
- Sihem Sassi-Gaha - Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United StatesDanielle T Loughlin - Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United StatesFrank Kappler - Dynamis Therapeutics Inc. Jenkintown, PA, United StatesMichael L Schwartz - Dynamis Therapeutics Inc. Jenkintown, PA, United StatesBangying Su - Dynamis Therapeutics Inc. Jenkintown, PA, United StatesAnnette M Tobia - Dynamis Therapeutics Inc. Jenkintown, PA, United StatesCarol M Artlett - Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States
- Publication Details
- Matrix biology, v 29(2)
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology
- Web of Science ID
- WOS:000275879400006
- Scopus ID
- 2-s2.0-76549095723
- Other Identifier
- 991014878159904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Biochemistry & Molecular Biology
- Cell Biology